Linear and cyclic amphiphilic peptides, (W<sub>4</sub>KR<sub>5</sub>) and [W<sub>4</sub>KR<sub>5</sub>], were evaluated as antibacterial agents against Gram-positive and Gram-negative bacteria, including four multi-drug resistant strains and the corresponding four non-resistant strains. Cyclic peptide [W<sub>4</sub>KR<sub>5</sub>] showed higher antibacterial activity than the linear (W<sub>4</sub>KR<sub>5</sub>) counterpart. Cyclic [W<sub>4</sub>KR<sub>5</sub>] was subjected to combination (physical mixture or covalent conjugation) with meropenem as a model antibiotic to study the impact of the combination on antimicrobial activity. A physical mixture of meropenem and [W<sub>4</sub>KR<sub>5</sub>] showed synergistic antibacterial activity against Gram-negative P. aeruginosa (ATCC BAA-1744) and P. aeruginosa (ATCC 27883) strains. [W<sub>4</sub>KR<sub>5</sub>] was further subjected to extensive antibacterial studies against additional 10 bacteria strains, showing significant antibacterial efficacy against Gram-positive bacteria strains. Combinations studies of [W<sub>4</sub>KR<sub>5</sub>] with an additional 9 commercially available antibiotics showed significant enhancement in antibacterial activity for all tested combinations, especially with tetracycline, tobramycin, levofloxacin, clindamycin, daptomycin, polymyxin, kanamycin, and vancomycin. Time-kill kinetics assay and flow cytometry results exhibited that [W<sub>4</sub>KR<sub>5</sub>] had a time-dependent synergistic effect and membrane disruption property. These data indicate that [W<sub>4</sub>KR<sub>5</sub>] improves the antibacterial activity, presumably by facilitating the internalization of antibiotics and their interaction with the intracellular targets. This study introduces a potential strategy for treating multidrug-resistant pathogens by combining [W<sub>4</sub>KR<sub>5</sub>] and a variety of classical antibiotics to improve the antibacterial effectiveness.